Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
1(6%)
Results Posted
10%(1 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_1
2
13%
Ph phase_3
6
38%
Ph not_applicable
3
19%
Ph phase_4
3
19%

Phase Distribution

2

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 3Large-scale testing
6(42.9%)
Phase 4Post-market surveillance
3(21.4%)
N/ANon-phased studies
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(10)
Terminated(2)
Other(3)

Detailed Status

Completed10
unknown3
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 36 (42.9%)
Phase 43 (21.4%)
N/A3 (21.4%)

Trials by Status

terminated213%
unknown319%
recruiting16%
completed1063%

Recent Activity

1 active trials
Showing 5 of 16
recruitingphase_4

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

NCT02347111
completed

Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation

NCT05279833
terminatedphase_1

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

NCT02153437
completednot_applicable

Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment

NCT03845010
completed

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

NCT04128878
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT02347111Phase 4

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Recruiting
NCT05279833

Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation

Completed
NCT02153437Phase 1

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Terminated
NCT03845010Not Applicable

Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment

Completed
NCT04128878

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

Completed
NCT03799536Phase 1

Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions

Completed
NCT03895411Phase 4

Efficacy and Safety of Sotalol in Children With Arrhythmia

Unknown
NCT02294955Not Applicable

Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)

Unknown
NCT00000531Phase 3

Antiarrhythmics Versus Implantable Defibrillators (AVID)

Completed
NCT00000556Phase 3

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Completed
NCT00000518Phase 3

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)

Completed
NCT01576042Not Applicable

Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator

Terminated
NCT02145546Phase 4

Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

Unknown
NCT00000464Phase 3

Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)

Completed
NCT00035451Phase 3

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

Completed
NCT00007605Phase 3

Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16